Fennec Provides Business Update and Announces First Quarter 2019 Financial Results Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty […]
Read More… from Fennec Provides Business Update and Announces First Quarter 2019 Financial Results